Radiation Oncology Patient Articles & Analysis
5 news found
“Our research shows that radiation oncologists and patients cite SOM as the most burdensome radiotherapy toxicity in head and neck cancer treatment, and there are currently no FDA-approved drugs to reduce the incidence or duration of SOM in solid tumors. ...
Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live ...
“Clear targeting of the tumor bed is essential for radiation therapy”, stated the lead author and radiation oncologist, Jaroslaw Hepel M.D., Director of Stereotactic Radiosurgery at Rhode Island Hospital and Associate Professor of Radiation Oncology at The Warren Alpert Medical School of Brown University. ...
However, given the surgical site often lies in soft tissue, exact identification of the native tumor bed can present some difficulty for radiation planning. The surgical and radiation oncology team at Providence Mission Hospital (Mission Viejo, Ca) elected to use a novel tumor bed marker called VeraForm for a sarcomatoid carcinoma. ...
Tarallo continued, “Theragenics has supported brachytherapy and the radiation oncology community for over 35 years. Leveraging our expertise and assets in our brachytherapy business, including our sales organization and our manufacturing capabilities in medical devices and nuclear medicine, is an important part of our strategy. We look forward to making ...